138 related articles for article (PubMed ID: 16937310)
1. Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient.
Hikino H; Kawashima M; Yamada T; Ozaki N
Int J Clin Oncol; 2006 Aug; 11(4):332-5. PubMed ID: 16937310
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.
Kahan Z; Uhercsak G; Hajnal-Papp R; Boda K; Thurzo L
Oncology; 2005; 68(4-6):446-53. PubMed ID: 16020975
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J
Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091
[TBL] [Abstract][Full Text] [Related]
5. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
7. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
Somlo G; Doroshow JH; Synold T; Longmate J; Reardon D; Chow W; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Shibata SI; Tetef ML; Yen Y; Kogut N; Schriber J; Alvarnas J
Br J Cancer; 2001 Jun; 84(12):1591-8. PubMed ID: 11401310
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting.
Burtness B; Windsor S; Holston B; DiStasio S; Staugaard-Hahn C; Abrantes J; Kneuper-Hall R; Farber L; Orell J; Bober-Sorcinelli K; Haffty BG; Reiss M
Cancer J Sci Am; 1999; 5(4):224-9. PubMed ID: 10439168
[TBL] [Abstract][Full Text] [Related]
9. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer.
Pippen J; Paul D; Vukelja S; Clawson A; Iglesias J
Breast Cancer Res Treat; 2011 Dec; 130(3):825-31. PubMed ID: 21976055
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
11. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.
Cho E; Wu Q; Rubinstein L; Linden H; Gralow J; Specht J; Gadi V; Ellis G
Breast J; 2018 Jul; 24(4):610-614. PubMed ID: 29532546
[TBL] [Abstract][Full Text] [Related]
13. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Hudis C; Seidman A; Baselga J; Raptis G; Lebwohl D; Gilewski T; Moynahan M; Sklarin N; Fennelly D; Crown JP; Surbone A; Uhlenhopp M; Riedel E; Yao TJ; Norton L
J Clin Oncol; 1999 Jan; 17(1):93-100. PubMed ID: 10458222
[TBL] [Abstract][Full Text] [Related]
14. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.
Hikino H; Yamada T; Johbara K; Obayashi N; Ozaki N
Breast; 2006 Feb; 15(1):97-9. PubMed ID: 16005228
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study in a variety of practice settings in Kyushu].
Anan K; Mitsuyama S; Taniguchi H; Yamamoto Y; Fujiyoshi K; Tateishi T; Tamura K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1417-22. PubMed ID: 17033230
[TBL] [Abstract][Full Text] [Related]
16. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
19. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Abu-Khalaf MM; Juneja V; Chung GG; DiGiovanna MP; Sipples R; McGurk M; Zelterman D; Haffty B; Reiss M; Wackers FJ; Lee FA; Burtness BA
Breast Cancer Res Treat; 2007 Sep; 104(3):341-9. PubMed ID: 17051423
[TBL] [Abstract][Full Text] [Related]
20. Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.
Abu-Khalaf MM; Windsor S; Ebisu K; Salikooti S; Ananthanarayanan G; Chung GG; DiGiovanna MP; Haffty BG; Abrams M; Farber LR; Hsu AD; Reiss M; Zelterman D; Burtness BA
Oncology; 2005; 69(5):372-83. PubMed ID: 16319508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]